

1 October 2024

## Company Secures R&D Loan Facility

**Perth, Australia, and Minneapolis, USA:** TrivarX Limited ('the Company') (ASX: TRI) is pleased to advise that the Company has entered into a short-term loan facility agreement with Kashcade RD1 Pty Ltd (**Lender**) for the amount of \$500,000 (**Loan**)..

The R&D loan facility has been established against the Company's anticipated R&D tax rebate for the FY24 period and will be used for working capital purposes.

The Loan has an establishment fee of 2% and bears interest of 1.38% per month with an initial maturity date of 30 November 2024 which can be extended for an additional 30 days upon agreement by the Lender.

**This announcement is authorised for release by the Board of Directors of TrivarX Limited.**

**ENDS**

### Investor Enquiries:

Henry Jordan – Six Degrees Investor Relations

[Henry.jordan@sdir.com.au](mailto:Henry.jordan@sdir.com.au)

+61 431 271 538

### About TrivarX Limited:

TrivarX (ASX: TRI) (OTCPINK: MDBIF) is a mental health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. The Company was founded in Australia, with offices located in Perth (WA) and Minneapolis (MN, USA). TrivarX is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on [www.otcm Markets.com](http://www.otcm Markets.com) and [www.asx.com.au](http://www.asx.com.au)